TP53 and cancer: SIRT7 assumes a pivotal role in safeguarding the survival of HCC cells in response to anti-cancer drugs predominantly through direct deacetylation of the tumor suppressor p53, thereby hampering p53-driven apoptotic pathway (Fig. 2D and Table 1) [62].